I have severe parathyroids, a chronic disease that can cause severe muscle spasms and joint pain.
Parathyroid therapy, which is used to treat it, has been around for years, but I never heard of anyone being able to actually use it.
Theoretically, the only way to treat severe parathysmal joint pain is to put a patch on it, but the patches usually do not last long.
Instead, you need to use a medication that helps to control spasms in the affected joint.
A new drug that helps control parathyrodysplasia and other symptoms of parathyroguiding is in development, called parathyrogenetic therapy (PTS).
According to a report from the National Institutes of Health, the drug could be available within two years.
The drugs use is being conducted at the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Cancer Institute (NCI), and is funded by the National Science Foundation.
The drug uses the same enzyme that gives rise to parathyroxine, which has been used for decades to treat the disease.
“This drug works on the enzyme that is in your muscles, called the parathyrotic protein,” Dr. Mark J. Smith, an assistant professor of medicine at the University of Florida, told Next Big News.
“So the enzyme is actually there to make a chemical that helps you to relax the muscle, and this enzyme can be used to relax muscle spasm.”
The drug, called Paxil, was developed by Pfizer in partnership with the NIAID and NCI, and was recently approved by the FDA.
Paxil is currently being tested in clinical trials for patients with severe paratherosclerosis.
Smith said it was important to remember that patients with milder conditions, such as arthritis or muscular dystrophy, have a lower incidence of parathiesclerosis.
He said Paxil can help to manage some symptoms in some patients, including spasm in the muscles.
“We think Paxil has a very modest effect, which makes it an important candidate in treating some milder symptoms,” Smith said.
“If you have a milder condition, Paxil should probably be used as a first-line therapy, but it has some potential as a second-line treatment.”
Paxil is available as a pill, tablet, spray, patch or capsule.
For the average person, Paxils dosage is 200 milligrams (mg) daily, Smith said, with the amount that would be prescribed for milder parathyritis.
Paxils effective dosage is approximately 300 mg daily.
In addition to Paxil’s effectiveness in treating milder joint spasms, the new drug can also help with other conditions such as migraines, insomnia and anxiety.
Smith explained that the FDA has approved the drug as a treatment for the common cold and other colds, and that it should be given to people at least 6 months after the onset of the disease, if possible.
Paxill is not recommended for use in the elderly or people with other medical conditions.
Smith added that he hopes the drug will be available in the next couple of years.
He added that Paxil would not be available to the general public for at least a decade, unless Pfizer and the N.I.A. collaborate on the drug’s development.
The NIAAD reported that the drug would be licensed by the Drug Enforcement Administration, which means that the NDA, or Federal Drug Administration, has approved it.
The agency is also conducting clinical trials to determine if the drug works as well as Paxil in people with severe cases of paratheroism.
Dr. Scott R. Smith is the associate director for the Center for Drug Evaluation and Research at NIAid.
Follow him on Twitter @ScottRSmith